Abstract
BackgroundThis systematic review aims to review the literature on trial-based economic evaluations of non-pharmacological interventions directly targeted at persons with dementia as well as persons with mild cognitive impairment and their respective caregivers.MethodsA systematic literature research was conducted for the timeframe from 2010 to 2016 in the following databases: Centre for Reviews and Dissemination, EconLit, Embase, Cochrane Library, PsycINFO and PubMed. Study quality was assessed according to the Drummond criteria.ResultsIn total sixteen publications were identified. Health economic evaluations indicated the cost-effectiveness of physical exercise interventions and occupational therapy. There was also evidence to suggest that psychological and behavioral therapies are cost-effective. Health economic studies investigating psychosocial interventions mainly targeted towards informal caregivers showed inconsistent results.ConclusionsDue to the increasing prevalence of dementia non-pharmacological interventions and their health economic impact are of increasing importance for health care decision-makers and HTA agencies.
Highlights
This systematic review aims to review the literature on trial-based economic evaluations of non-pharmacological interventions directly targeted at persons with dementia as well as persons with mild cognitive impairment and their respective caregivers
The aim of this article is to conduct a systematic review of recent trial-based economic evaluations and cost studies of non-pharmacological interventions directly targeted at people living with dementia (PwD), persons with mild cognitive impairment (PwMCI) or their informal caregivers
Two articles are based on results from the British strategy intervention (START) (STrAtegies for RelaTives) study [18, 19]
Summary
This systematic review aims to review the literature on trial-based economic evaluations of non-pharmacological interventions directly targeted at persons with dementia as well as persons with mild cognitive impairment and their respective caregivers. Estimates show that there are around 47 million people living with dementia (PwD) worldwide [1]. Acetylcholinesterase inhibitors provide small but clinically important symptomatic benefits on cognition and function for persons with Alzheimer’s disease (AD), the most prevalent subtype of dementia, persons with Lewy body dementia and Parkinson’s disease dementia, without counteracting the over the last decade non-pharmacological interventions for PwDs and persons with mild cognitive impairment (PwMCI) as well as their caregivers became more important, leading to a considerable growth in the evidence base [5, 6]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
